Navigation Links
Fluxion Biosciences Receives National Cancer Institute Grant for Development of ERASE-Seq Liquid Biopsy Technology
Date:2/27/2019

Fluxion Biosciences, a leading developer of precision solutions for life science research and diagnostics, today announced that it has received a National Cancer Institute grant for further development of its ERASE-Seq liquid biopsy technology. The Phase I grant will have a duration of 9 months, with clinical support from the lab of Dr. Omar Mian at the Cleveland Clinic.

Liquid biopsies offer the potential to improve treatment of cancer by providing affordable, non-invasive detection of actionable cancer mutations from a blood sample. However, the relative abundance of cancer DNA in blood is extremely low, and below the detection threshold for most assays. Analytical and clinical results have demonstrated that ERASE-Seq provides superior results compared to competitive approaches for sequencing circulating tumor DNA (ctDNA) isolated from blood.

The NCI project includes three main aims: 1) improvements to and validation of the ERASE-Seq bio-informatic algorithms to improve detection sensitivity and specificity, 2) automation of the ERASE-Seq data analysis pipeline, and 3) measuring sensitivity and accuracy of ERASE-Seq to competitive sequencing approaches and to an established “gold standard” technique using cancer patient blood samples.

“We are honored to receive this NCI grant and excited to develop the capabilities of our ERASE-Seq liquid biopsy”, stated Jeff Jensen, CEO. "Liquid biopsies offer tremendous promise, but advances are needed to improve the sensitivity and accuracy of these tests. ERASE-Seq offers the potential to deliver on the promise of cancer precision medicine: the right treatment for the right patient at the right time. We look forward to collaborating with Cleveland Clinic on this important program.”

Dr. Mian, Assistant Professor of Radiation Oncology at Cleveland Clinic, stated, “This collaboration demonstrates the innovation expected of a Small Business Innovative Research grant. It will provide the basis for the first ctDNA diagnostic for hepatocellular carcinoma, effectively changing the way the disease is diagnosed in the clinic. Additionally, if successful this will introduce researchers in other areas of oncology to a powerful method for ctDNA variant analysis.”

About Fluxion Biosciences

Fluxion’s liquid biopsy solutions are revolutionizing how cancer is detected and treated. Fluxion’s pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion’s technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion's liquid biopsy capabilities, visit liquidbiopsy.fluxionbio.com.

Read the full story at https://www.prweb.com/releases/fluxion_biosciences_receives_national_cancer_institute_grant_for_development_of_erase_seq_liquid_biopsy_technology/prweb16127477.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Inflection Biosciences licenses preclinical oncology programs from the CNIO
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Springer will publish lecture series with the Mathematical Biosciences Institute
4. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
5. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
6. The new Africa -- green shoots in biosciences
7. Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
8. ACEA Biosciences Introduces an Exploratory xCELLigence® RTCA S16 Instrument
9. ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.
10. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
11. Tosoh Bioscience LLC invests in Semba Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/13/2019)... ... ... Sleep problems constitute a global epidemic that threatens health and quality of ... billion people worldwide suffer from sleep apnea - a condition that occurs when ... go undiagnosed. Today, Beddr , the sleep health technology startup, announced its participation ...
(Date:3/11/2019)... ... March 11, 2019 , ... A new report published by the ... to previous generations; 77% of those aged 18 to 35 already have or are ... those aged 55 and older.(1) Among all LGBTQ prospective parents, 41% are considering assisted ...
(Date:3/9/2019)... ... , ... A firm believer in causes greater than all of us, Makers ... will help fund not only research to find a cure, but services that provide ... on the lookout for ways to make a difference. When The Leukemia & Lymphoma ...
Breaking Biology News(10 mins):
(Date:3/5/2019)... ... 2019 , ... Modality Solutions, an Inc. Verified Company, ... network experts, and experienced integrated staffing professionals. , Upon receiving Modality ... program, Inc. editors independently reviewed the Houston-based cold chain management company to validate ...
(Date:2/27/2019)... SEABROOK, N.H. (PRWEB) , ... February 26, 2019 ... ... system integrator of custom industrial automation and IT solutions with 140 employees on ... recently earned his professional engineer’s license in the State of New Hampshire. Sandmaier, ...
(Date:2/22/2019)... , ... February 20, 2019 , ... Superior Controls, ... IT solutions with 140 employees on both the east and west coasts, today announced ... Manager working out of the company’s Seabrook, New Hampshire office. In his new ...
(Date:2/16/2019)... TORONTO (PRWEB) , ... February 14, 2019 , ... ... data visualization, analytics, and knowledge sharing capability that also provides the flexibility for ... and play” functionality. It also provides a shared workbench to conduct quick analytics ...
Breaking Biology Technology: